Ab
Ablynx (Sanofi)
Ghent BEFounded 2001400 employees
Private CapbiotechAcquiredRare DiseaseHematology
Platform: Nanobody
Market Cap
N/A
All Drugs
2
Clinical Trials
3
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| ABL-5779 | ABL-5779 | Phase 1/2 | 1 | WRN | ADHD | ||
| ABL-1749 | ABL-1749 | Phase 1 | 2 | TROP-2 | ALL |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)